Price (delayed)
$18.36
Market cap
$270.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$14.3
Enterprise value
$88.26M
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
There are no recent dividends present for TECX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.